NEWS - 2009
In conversation with Tom Reeves
As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been. For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.
Interface Biologics Expands Scientific Advisory Board
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Board ("SAB").
Biomedical Polymer Is Proving to be a Powerful Infection Fighter that Protects Patients
Just about everyone on
the planet will get a sliver of something in a finger at one time or
another. Whether it is wood, metal, plastic or glass, if you don’t get
it out, it soon becomes a painful mess of infection. Your body is just
not meant to have foreign things and bad bacteria
inside it. Period.
Download Full Article (English PDF)
?Un polymère biomédical devient un puissant allié dans la lutte contre les infections
À peu près tout le monde sur la planète recevra, un jour ou l’autre, un éclat de quelque chose dans le doigt. Qu’il soit de bois, de métal, de plastique ou de verre, si vous ne le retirez pas, votre doigt ne tardera pas à vous faire mal et à s’infecter. Votre organisme ne tolère tout simplement pas que des corps étrangers et de mauvaises bactéries y pénètrent, un point c’est tout.
Télécharger l'article complet (PDF français)
Antimicrobial-Infused Polymer Demonstrates Backbone
Implants often rely on antimicrobial coatings to prevent infections. But the release of antibacterial agents via diffusion from a biomaterial’s surface may not be the most effective approach for combating biofilm formation on implants. With this in mind, Interface Biologics (Toronto; www.interfacebiologics.com) is developing a technology platform that it claims will prevent biofilm formation more effectively than coatings, last longer in the body, and kill a broader spectrum of microbes.
Interface Biologics Appoints Arthur L. Rosenthal, Ph.D. to Board of Directors
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today that experienced medical device executive, Arthur L. Rosenthal Ph.D., has been appointed to its Board of Directors.